These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 11727316)
21. Optimizing the use of open-source software applications in drug discovery. Geldenhuys WJ; Gaasch KE; Watson M; Allen DD; Van der Schyf CJ Drug Discov Today; 2006 Feb; 11(3-4):127-32. PubMed ID: 16533710 [TBL] [Abstract][Full Text] [Related]
22. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Bugrim A; Nikolskaya T; Nikolsky Y Drug Discov Today; 2004 Feb; 9(3):127-35. PubMed ID: 14960390 [TBL] [Abstract][Full Text] [Related]
23. Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries. Cruz-Monteagudo M; Borges F; Cordeiro MN; Cagide Fajin JL; Morell C; Ruiz RM; Cañizares-Carmenate Y; Dominguez ER J Comb Chem; 2008; 10(6):897-913. PubMed ID: 18855460 [TBL] [Abstract][Full Text] [Related]
24. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. Ebbels TM; Keun HC; Beckonert OP; Bollard ME; Lindon JC; Holmes E; Nicholson JK J Proteome Res; 2007 Nov; 6(11):4407-22. PubMed ID: 17915905 [TBL] [Abstract][Full Text] [Related]
25. Quantitative proteomics for drug toxicity. Gao Y; Holland RD; Yu LR Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682 [TBL] [Abstract][Full Text] [Related]
26. A novel in silico approach to drug discovery via computational intelligence. Hecht D; Fogel GB J Chem Inf Model; 2009 Apr; 49(4):1105-21. PubMed ID: 19348414 [TBL] [Abstract][Full Text] [Related]
27. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Yang Y; Blomme EA; Waring JF Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262 [TBL] [Abstract][Full Text] [Related]
28. Exploration of cluster structure-activity relationship analysis in efficient high-throughput screening. Wang XS; Salloum GA; Chipman HA; Welch WJ; Young SS J Chem Inf Model; 2007; 47(3):1206-14. PubMed ID: 17480051 [TBL] [Abstract][Full Text] [Related]
29. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Tanrikulu Y; Schneider G Nat Rev Drug Discov; 2008 Aug; 7(8):667-77. PubMed ID: 18636071 [TBL] [Abstract][Full Text] [Related]
30. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Dokoumetzidis A; Kalantzi L; Fotaki N Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):491-505. PubMed ID: 17696801 [TBL] [Abstract][Full Text] [Related]
31. Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction. Venkatapathy R; Moudgal CJ; Bruce RM J Chem Inf Comput Sci; 2004; 44(5):1623-9. PubMed ID: 15446819 [TBL] [Abstract][Full Text] [Related]
37. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here? Stevens JL Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225 [TBL] [Abstract][Full Text] [Related]
38. PowerMV: a software environment for molecular viewing, descriptor generation, data analysis and hit evaluation. Liu K; Feng J; Young SS J Chem Inf Model; 2005; 45(2):515-22. PubMed ID: 15807517 [TBL] [Abstract][Full Text] [Related]